SAMRATPH
New to Zerodha? Sign-up for free.
New to Zerodha? Sign-up for free.
Get instant stock alerts
- Share Price
- Financials
- Revenue mix
- Shareholdings
- Peers
- Forensics
Share Price
Coming soon
- 5D
- 1M
- 6M
- YTD
- 1Y
- 5Y
- MAX
Financials
-
Summary
-
Profit & Loss
-
Balance sheet
-
Cashflow
| (In Cr.) |
|---|
| (In Cr.) | ||||
|---|---|---|---|---|
|
This data is currently unavailable for this company. |
| (In %) |
|---|
| (In Cr.) |
|---|
| Financial Year (In Cr.) |
|---|
Revenue mix
-
Product wise
-
Location wise
Revenue Mix
This data is currently unavailable for this company.
Revenue Mix
This data is currently unavailable for this company.
Forensics
Recent events
-
News
-
Corporate Actions
This data is currently unavailable for this company.
Events:
Dividend
Dividend
Dividend
Dividend
More Nano Cap Ideas
See similar 'Nano' cap companies with recent activity
Promoter Buying
Companies where the promoters are bullish
Capex
Companies investing on expansion
Superstar Investor
Companies where well known investors have invested
Popular questions
-
Business
-
Financials
-
Share Price
-
Shareholdings
What does Samrat Pharmachem do?
Samrat Pharmachem Ltd specializes in manufacturing iodine salts & bromine salts used in various industries such as Pharmaceuticals, Chemicals, Food, Fertilizer, Salt, etc.
Who are the competitors of Samrat Pharmachem?
Samrat Pharmachem major competitors are JFL Life Sciences, Kabra Drugs, Amwill Health Care, Asston Pharma, Zenith Drugs, Bacil Pharma, Accretion Pharma.. Market Cap of Samrat Pharmachem is ₹65 Crs. While the median market cap of its peers are ₹69 Crs.
Is Samrat Pharmachem financially stable compared to its competitors?
Samrat Pharmachem seems to be financially stable compared to its competitors. The probability of it going bankrupt or facing a financial crunch seem to be lower than its immediate competitors.
Does Samrat Pharmachem pay decent dividends?
The company seems to be paying a very low dividend. Investors need to see where the company is allocating its profits. Samrat Pharmachem latest dividend payout ratio is 4.34% and 3yr average dividend payout ratio is 6.83%
How has Samrat Pharmachem allocated its funds?
Companies resources are allocated to majorly unproductive assets like Capital Work in Progress, Inventory, Short Term Loans & Advances
How strong is Samrat Pharmachem balance sheet?
Balance sheet of Samrat Pharmachem is strong. It shouldn't have solvency or liquidity issues.
Is the profitablity of Samrat Pharmachem improving?
The profit is oscillating. The profit of Samrat Pharmachem is -₹1.68 Crs for TTM, ₹7.11 Crs for Mar 2025 and ₹2.16 Crs for Mar 2024.
Is the debt of Samrat Pharmachem increasing or decreasing?
The net debt of Samrat Pharmachem is decreasing. Latest net debt of Samrat Pharmachem is ₹0.56 Crs as of Sep-25. This is less than Mar-25 when it was ₹9.63 Crs.
Is Samrat Pharmachem stock expensive?
Samrat Pharmachem is not expensive. Latest PE of Samrat Pharmachem is 0, while 3 year average PE is 19.86. Also latest EV/EBITDA of Samrat Pharmachem is 0.0 while 3yr average is 26.32.
Has the share price of Samrat Pharmachem grown faster than its competition?
Samrat Pharmachem has given lower returns compared to its competitors. Samrat Pharmachem has grown at ~-42.91% over the last 1yrs while peers have grown at a median rate of -28.96%
Is the promoter bullish about Samrat Pharmachem?
Promoters stake in the company seems stable, and we need to go through filings and allocation of resources to gauge promoter bullishness. Latest quarter promoter holding in Samrat Pharmachem is 49.09% and last quarter promoter holding is 49.09%.
Are mutual funds buying/selling Samrat Pharmachem?
There is Insufficient data to gauge this.
